News Medical on MSN10d
High discontinuation rates of GLP-1 agonists found among patients with obesityDiscontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...
GlobalData on MSN7d
Palatin concludes Phase II trial of combination therapy for obesityPalatin Technologies has completed its Phase II study, BMT-801, evaluating the joint administration of melanocortin 4 ...
a glucagon-like peptide-1 (GLP-1)/gastric inhibitory polypeptide (GIP), to treat obesity. The final output collection and quality control will be completed soon, with top-line data anticipated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback